Search Results
Jun 17, 2026, 08:25 ET IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Jun 17, 2026, 08:01 ET Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026
Among 41 evaluable patients, confirmed partial responses (PRs) were observed across multiple tumor types, including gastric, bladder, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and melanoma.The study population represented a particularly challenging treatment setting,
More news about: Nectin Therapeutics, LTD.
Jun 17, 2026, 05:00 ET CHOP Scientists Engineer Personalized Cartilage Graft for Infants with Life-Threatening Airway Narrowing
and we may be able to apply the technology to other conditions that require a cartilage graft."This study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health grant R21HL159521, Children's Hospital of Philadelphia Research Institute, the Frontier Program
More news about: Children's Hospital of Philadelphia
Jun 16, 2026, 10:01 ET PD-L1 Biomarker Testing Market to Reach USD 1,830.7 Million by 2036 as Precision Oncology and Immunotherapy Adoption Accelerate Global Demand
levels.PD-L1 assays are becoming critical for selecting patients eligible for immune checkpoint inhibitors, particularly in oncology indications such as lung cancer, melanoma, and renal cell carcinoma. Rising integration of biomarker testing into standard oncology workflows is strengthening long-term market
More news about: Future Market Insights
Jun 16, 2026, 08:39 ET CARD Expresses Gratitude to Libby Community as It Prepares to Close Patient Services at End of August
meeting federal grant closeout requirements.CARD intends to continue grant-funded services through August 31, including asbestos health screening, lung cancer screening, case management, outreach, and education. However, CARD will no longer provide long-distance screening services because those services
More news about: Center for Asbestos Related Disease, Inc. (CARD)
Jun 16, 2026, 08:00 ET 再鼎醫藥宣布Zocilurtatug Pelitecan（Zoci）獲歐洲藥品管理局孤兒藥資格認定，用於治療來源於肺的神經內分泌癌
參考文獻：[1] J Thorac Oncol. 2023 Jan:18(1):31-46; Lung Cancer Foundation of America[2]
More news about: 再鼎醫藥
Jun 16, 2026, 07:30 ET SpliSense Secures Up to $13 Million from the Cystic Fibrosis Foundation to Advance Phase 2b Study of SPL84 for Cystic Fibrosis
positive SPL84 Phase 2a clinical results demonstrating the first-ever clinical proof-of-concept for an inhaled antisense oligonucleotide therapy in a lung diseaseFunding supports the ongoing global Phase 2b study evaluating SPL84 in people with cystic fibrosis carrying the 3849+10kb C→T mutation
More news about: SpliSense
Jun 16, 2026, 07:00 ET Cizzle Bio Announces Laboratory Validation of CIZ1B Biomarker Blood Test for Early Lung Cancer at OmniHealth Diagnostics
appear until the disease has advanced, lung cancer is frequently diagnosed at later stages, when five-year survival rates can fall to approximately 10%. By contrast, five-year survival rates approach 65% when lung cancer is detected early, according to the American Lung Association.While approximately
More news about: Cizzle Bio
Jun 15, 2026, 12:31 ET EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
Non-Small Cell Lung Cancer MarketNon-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding
More news about: DelveInsight Business Research, LLP
Jun 15, 2026, 08:45 ET Bybit Launches RWA Earn, Bringing Institutional Investment Opportunities On-Chain to Eligible Users
ecosystem framework which provides the RWA infrastructure layer. Underlying assets are held in institutional custody by State Street Bank (PDO) and CMB Wing Lung Trustee (CMIGB) respectively.No subscription or redemption fees apply. All on-chain gas fees are borne by Bybit for both products.
More news about: Bybit
Jun 15, 2026, 08:29 ET Bybit Launches RWA Earn, Bringing Institutional Investment Opportunities On-Chain to Eligible Users
ecosystem framework which provides the RWA infrastructure layer. Underlying assets are held in institutional custody by State Street Bank (PDO) and CMB Wing Lung Trustee (CMIGB) respectively.No subscription or redemption fees apply. All on-chain gas fees are borne by Bybit for both products.
More news about: Bybit
Jun 15, 2026, 07:45 ET TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
as either monotherapy (n=24) or in combination with pembrolizumab (n=15) among patients with advanced, therapy refractory cancers, including breast, lung, colorectal, and ovarian cancer. The purpose of the study was to investigate its safety profile and determine the recommended Phase 2 dose for solid
More news about: TuHURA Biosciences, Inc.
Jun 15, 2026, 06:00 ET IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDE892 monotherapy expansion is anticipated in Q3 2026MTAP-deletion is estimated to occur in up to 40% of pancreatic cancer and ~15% of non-small cell lung cancer (NSCLC)SOUTH SAN FRANCISCO, Calif., June 15, 2026 /PRNewswire/
More news about: IDEAYA Biosciences, Inc.
Jun 15, 2026, 02:52 ET Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
for the treatment of advanced breast cancer. HER3 is broadly expressed across various solid tumors, including breast, ovarian, colon, gastric, lung, skin, and pancreatic cancers, affecting millions of patients globally. While traditional HER3-targeted ADCs have demonstrated therapeutic potential
More news about: Akeso, Inc.
Jun 12, 2026, 17:19 ET The Inner Circle acknowledges, Michael M. Pennock, MD, MBiot, DABR as a Pinnacle Lifetime Member
lives of cancer patients through his precision, compassion, and commitment to care. Treating adult patients facing a wide range of cancers including lung, breast, head and neck, gastrointestinal, prostate, brain, and spine, Dr. Pennock is known for his meticulous attention to detail and his ability to
More news about: The Inner Circle
Jun 12, 2026, 15:35 ET PROCURE PROTON THERAPY CENTER CELEBRATES JOSEPH AS ITS 8,000TH PATIENT
transformative power of proton therapy."ProCure, located in nearby Somerset, NJ, treats a range of cancers, including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases.Added Wang: "Surpassing this milestone has taken
More news about: ProCure Proton Therapy Center
Jun 12, 2026, 15:09 ET Allegheny Health Network's Biomarker Moonshot Cancer Research Program Marks Five-Year Milestone, Enrolling More Than 11,000 Patients Across All Cancer Types
spanning the full cancer continuum from early-stage disease to advanced malignancies. The most frequently represented disease sites include breast, lung, uterine, colorectal, ovarian, skin, blood, prostate, pancreatic, and kidney cancers, reflecting the program's broad and inclusive scope.At the
More news about: Allegheny Health Network
Jun 12, 2026, 12:03 ET Inaugural 'Here Comes Summer' Benefit Fuels Lung Cancer Research, Honors Legacy of Donna Summer
many ways to help people with lung cancer today." Dr. Spigel went on to say,"Research is just integral to lung cancer care. The science is there. We can understand targets, we can design drugs, we can run trials. But all of this takes effort and investment. Your support of lung cancer research is an important
More news about: Lung Cancer Research Foundation
Jun 12, 2026, 08:00 ET Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
trial is sponsored by Jazz's partner, PharmaMar. About Small Cell Lung Cancer In the U.S., approximately 13 percent of lung cancers are small cell.1 Approximately 30,000 new cases of small cell lung cancer (SCLC) are reported in the U.S. each year.2 The risk for
More news about: Jazz Pharmaceuticals plc
Jun 12, 2026, 06:30 ET Gundry MD Introduces "Everyday Essentials" -- A Curated Line of 14 Foundational Wellness Supplements
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 25 years helping people restore
More news about: Gundry MD
Jun 12, 2026, 03:32 ET Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
pneumonia of unknown etiology, characterized by fibrosis that primarily affects the pulmonary interstitium, leading to stiffening and loss of elasticity of lung tissue, and ultimately resulting in respiratory failure. Current medical treatments cannot completely reverse pulmonary fibrosis; from the time of diagnosis,
More news about: Simcere Pharmaceutical Group Limited
Jun 12, 2026, 02:59 ET Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
pneumonia of unknown etiology, characterized by fibrosis that primarily affects the pulmonary interstitium, leading to stiffening and loss of elasticity of lung tissue, and ultimately resulting in respiratory failure. Current medical treatments cannot completely reverse pulmonary fibrosis; from the time of diagnosis,
More news about: Simcere Pharmaceutical Group Limited
Jun 11, 2026, 10:01 ET OxiWear Announces Medicare and Insurance Coverage Expansion for Continuous Oxygen Measuring Device
device is designed to support patients with conditions including pulmonary hypertension, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), cardiovascular disease, sleep-related breathing disorders, and other conditions that may result in oxygen desaturation.Healthcare
More news about: OxiWear
Jun 11, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
Jun 11, 2026, 09:05 ET Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.